Home
Resources
Publications
Pilot Study of Zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in Patients With Refractory Partial Seizures

Pilot Study of Zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in Patients With Refractory Partial Seizures

J C Sackellares, P D Donofrio, J G Wagner, B Abou-Khalil, S Berent, K Aasved-Hoyt

Epilepsia. May-Jun 1985;26(3):206-11.

PMID: 3924586

Abstract:

A new anticonvulsant compound, zonisamide (1,2 benzisoxazole-methanesulfonamide), was studied in 10 adults with medically refractory partial seizures. Following a single oral dose of 400 mg, peak plasma levels occurred an average of 2.8 h after dosing, and the mean clearance from plasma was 2.34 L/h. Whole blood concentrations were higher than plasma concentrations because of red blood cell binding. Steady-state plasma concentrations were higher than predicted from a linear kinetic model. In most patients, seizure frequency was reduced after zonisamide was substituted for a standard antiepileptic drug. Dose-related reversible side effects in the central nervous and gastrointestinal systems were observed. Most patients tolerated doses between 5.2 and 12.5 mg/kg/day.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP73101641	Zonisamide Related Compound A		73101-64-1	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: